31/08/2025
Experimental EGFR/HER2 Tumor Vaccine:
This is a USDA regulated scientific study. Enrollment is limited to dogs with 🐾osteosarcoma, hemangiosarcoma and transitional cell carcinoma. 🐾
The vaccine is currently provided at no charge to the owner. As this is not a fully funded study, all costs associated with office visits, diagnostics and vaccine administration are the responsibility of the owner. If the vaccine receives approval, it will no longer be provided at no cost.
MedVet Chicago, MedVet Cincinnati, MedVet Cleveland, MedVet Pittsburgh, and MedVet Salt Lake City are currently enrolling patients.
In order to ensure all patients meet the enrollment criteria of having an expected prognosis that is greater than three months, MedVet hospitals are currently limiting enrollment to patients who are receiving appropriate standard of care therapies which may include surgery, chemotherapy, and/or radiation therapy depending on the tumor type. Patients being screened for enrollment with the intent to use the vaccine as a single agent treatment will not be considered.
Study Enrollment Criteria
Histologically (biopsy) confirmed diagnosis of osteosarcoma, hemangiosarcoma, or transitional cell carcinoma. An exception may be made if the dog has a long bone (limb) lesion consistent with osteosarcoma and the owner has elected not to pursue amputation.
If amputation is planned, the first dose of vaccine can be administered following the amputation.
Anticipated survival of greater than 3 months as determined by the evaluating oncologist.
While dogs with metastases may be enrolled in the study, this will be based on the extent/volume of disease and prognosis.
Dogs cannot be enrolled if they are receiving other immunotherapies or alternative therapies or are enrolled in another clinical study. Traditional chemotherapy and radiation therapy are allowed.
Required Testing
All costs associated with evaluation and testing are the responsibility of the pet owner and are not covered by the study. You will be provided with a cost estimate for all required and any additional recommended testing.
Chest X-rays, CBC, biochemical profile, and urinalysis at baseline prior to vaccine administration. Testing completed within seven days will likely be acceptable.
Chest X-rays must be repeated at 3, 6, and 9 months
A blood sample will be collected at each visit (baseline, day 21, day 40-50, 3 months, 6 months, 9 months) for research purposes.
Strict adherence to the vaccine administration guidelines is required. A booster vaccine must be given 21 days following the initial dose. It is allowable to administer the booster 1 day early or up to 7 days late if necessary due to appointment availability or if the administration day falls on a weekend or holiday.
For questions, please e-mail [email protected].
